FDA and European Medicines Agency release joint principles for artificial intelligence in medicine development
The FDA and European Medicines Agency issued joint principles for AI use in drug development. This guidance seeks to ensure safety as industry adoption grows.
Insights:
Regulators in the US 
USand the EU 
EUhave reached a significant milestone in pharmaceutical oversight with the joint issuance of principles for the safe and responsible use of artificial intelligence in drug development. Released on Wednesday, January 14, 2026, the guidance marks the first coordinated effort by the U.S. Food and Drug Administration and the European Medicines Agency to establish a framework for AI across the entire lifecycle of a medicine. This initiative is designed to accelerate innovation while ensuring that patient safety remains the primary focus as technology evolves.
USand the EU EUhave reached a significant milestone in pharmaceutical oversight with the joint issuance of principles for the safe and responsible use of artificial intelligence in drug development. Released on Wednesday, January 14, 2026, the guidance marks the first coordinated effort by the U.S. Food and Drug Administration and the European Medicines Agency to establish a framework for AI across the entire lifecycle of a medicine. This initiative is designed to accelerate innovation while ensuring that patient safety remains the primary focus as technology evolves.
